Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder.
Sexual dysfunction is a complaint of 30-50% of American women. Aside from hormone replacement therapy, there are no current FDA-approved medical treatments for female sexual complaints. The goal of this pilot study was to determine safety and efficacy of sildenafil for use in women with sexual arousal disorder (SAD). Evaluations were completed on 48 women with complaints of SAD. Physiologic measurements, including genital blood flow, vaginal lubrication, intravaginal pressure-volume changes, and genital sensation were recorded pre- and postsexual stimulation at baseline and following 100 mg sildenafil. Subjective sexual function was assessed using a validated sexual function inventory at baseline and following 6 weeks of home use of sildenafil. At termination of the study patients also completed an intervention efficacy index (FIEI). Following sildenafil, poststimulation physiologic measurements improved significantly compared to baseline. Baseline subjective sexual function complaints, including low arousal, low desire, low sexual satisfaction, difficulty achieving orgasm, decreased vaginal lubrication, and dyspareunia also improved significantly following 6 weeks home use of sildenafil. Sildenafil appears to significantly improve both subjective and physiologic parameters of the female sexual response. Double-blind, placebo-controlled studies are currently in progress to further determine efficacy of this medication for treatment of female sexual dysfunction complaints in different populations of women.
Berman
J R
JR
Department of Urology and Biostatistics, Boston Medical Center, Boston, Massachusetts, USA. drjenberman@yahoo.com
Berman
L A
LA
Lin
H
H
Flaherty
E
E
Lahey
N
N
Goldstein
I
I
Cantey-Kiser
J
J
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004414:Dyspareunia / Q000188:drug therapy; D005260:Female; D005836:Genitalia, Female / Q000098:blood supply / Q000000981:diagnostic imaging / Q000187:drug effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D010775:Photic Stimulation; D010865:Pilot Projects; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use*; D011687:Purines; D012684:Sensory Thresholds / Q000187:drug effects; D012725:Sexual Behavior / Q000187:drug effects; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*; D000068677:Sildenafil Citrate; D013450:Sulfones; D011795:Surveys and Questionnaires; D013997:Time Factors; D018608:Ultrasonography, Doppler; D014621:Vagina / Q000737:chemistry
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate